Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections Clinical Trial

Official title:

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 (NUMAX TM), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00192465
• Other study ID #: MI-CP101
• Status: Completed
• Phase: Phase 1
• First received: September 13, 2005
• Last updated: January 28, 2009
• Start date: November 2003
• Est. completion date: November 2004

Study information

• Verified date: January 2009
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To provide safety, tolerability, pharmacokinetic, and immunogenicity data for MEDI-524 administered initially as a single dose to healthy adults in a dose escalation safety study before testing in the targeted pediatric population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 2004
• Est. primary completion date: April 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Volunteers must meet all of the following criteria:

• Age 18 through 49 years at the time of administration of study drug

• Weight £90 kg

• Healthy by medical history and physical examination

• Normal electrocardiogram (EKG) at screening (must be within 21 days before entry into the study)

• Written informed consent obtained from the volunteer

• Sexually active females, unless surgically sterile, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 14 days prior to the administration of study drug, must agree to continue using such precautions for 30 days after administration of study drug, and must have a negative serum pregnancy test within 7 days prior to the administration of study drug and a negative urine pregnancy test on the day of study drug administration.

• Ability to complete the follow-up period of 90 days (single-dose groups) or 120 days (two-dose group) as required by the protocol

Exclusion Criteria:

• Volunteers must have none of the following:

• Acute illness at the time of entry into the study

• Temperature ³99.5°F at the time of entry into the study

• Any drug therapy within 7 days prior to Study Day 0 (except for certain medications such as contraceptives, topical corticosteroids, or infrequent use of over-the-counter headache medications, following approval of the sponsor)

• Blood donation in excess of 400 mL within 6 months of the time of entry into the study

• Receipt of immunoglobulin or blood products within 60 days before entry into the study

• Receipt of any investigational drug therapy or standard vaccine within 120 days before administration of study drug in this protocol through 60 days after the final dose of study drug

• History of immunodeficiency or receipt of immunosuppressive drugs

• History of allergic disease or reactions likely to be exacerbated by any component of the study drug

• Previous medical history or evidence of an intercurrent illness that may compromise the safety of the volunteer in the study

• Evidence of any systemic disease on physical examination

• Evidence of infection with hepatitis A, B, or C virus or HIV-1

• At screening (must be within 7 days before study dose administration) any of the following: CBC: Hgb < 12.0 gm/dL; WBC < 4,000/mm3; platelet count < 120,000/mm3 (or laboratory normal values); AST, ALT, BUN, creatinine > upper limit of normal; other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant.

• Nursing mother

• History of alcohol or drug abuse within the past 2 years

• The presence of any condition or concern which in the opinion of the principal investigator may interfere with the conduct or interpretation of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Respiratory Syncytial Virus Infections
• Virus Diseases

Intervention

Biological:
• MEDI-524 (Numax-TM)
Grp.1: 3 mg/kg IV (single dose)
• MEDI-524 (Numax-TM)
Grp. 2: 15 mg/kg IV (single dose)
• MEDI-524 (Numax-TM)
Grp. 3: 30 mg/kg IV (single dose)
• MEDI-524 (Numax-TM)
Grp. 4: 3 mg/kg IM (single dose)
• MEDI-524 (Numax-TM)
Grp.5: 3 mg/kg IM (two doses)

Locations

Country	Name	City	State
United States	SFBC International, Inc	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety		30 days after patient's final dose of study drug	Yes
Primary	Pharmacokinetics		Study Day 0 and 60, 90 days after dose 1; and 7, 30, 60, 90 days after dose 2.	No
Primary	Immunogenicity		150 days after final dose	No